Alcor advances kidney vitrification research with 40% success rate in preclinical models; begins antifreeze-protein gene therapy trials

Alcor Life Extension Foundation/Human and Organ Cryopreservation

Alcor demonstrated that kidney vitrification succeeds in approximately 40% of preclinical cases, using optimized cryoprotectant formulations. Additionally, Alcor initiated gene therapy trials integrating antifreeze-protein genes into cells to reduce cryodamage. These advances support Alcor's goal of reversible organ preservation and eventual revival therapies.